S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Price, News & Analysis

$2.38
-0.02 (-0.83%)
(As of 03/27/2024 ET)
Today's Range
$2.36
$2.44
50-Day Range
$1.89
$2.56
52-Week Range
$1.11
$3.65
Volume
43,391 shs
Average Volume
315,092 shs
Market Capitalization
$193.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.80

ProQR Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.7% Upside
$3.80 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of ProQR Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.37) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

694th out of 939 stocks

Pharmaceutical Preparations Industry

316th out of 422 stocks

PRQR stock logo

About ProQR Therapeutics Stock (NASDAQ:PRQR)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Stock Price History

PRQR Stock News Headlines

StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Hold
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
PRQR Mar 2024 2.500 call
ProQR Therapeutics N.V.
4 Biotech Stocks With Massive Buy Potential
Is ProQR (PRQR) Stock a Solid Choice Right Now?
ProQR Therapeutics NV PRQR
Positive Report for ProQR (PRQR) from Chardan Capital
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
3/27/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
156
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.80
High Stock Price Target
$5.00
Low Stock Price Target
$1.80
Potential Upside/Downside
+59.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,430,000.00
Net Margins
-431.65%
Pretax Margin
-426.98%

Debt

Sales & Book Value

Annual Sales
$7.05 million
Book Value
$0.55 per share

Miscellaneous

Free Float
74,521,000
Market Cap
$193.64 million
Optionable
Optionable
Beta
0.20
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 68)
    Founder & Independent Chairman of Supervisory Board
    Comp: $80.36k
  • Mr. Daniel Anton de Boer (Age 41)
    Founder, CEO & Member of Management Board
    Comp: $1.3M
  • Mr. Rene K. Beukema (Age 60)
    Chief Corporate Development Officer, General Counsel & Member of Management Board
    Comp: $993.69k
  • Dr. Gerard Platenburg (Age 60)
    Co-Founder & Chief Scientific Officer
    Comp: $23.89k
  • Mr. Jurriaan Dekkers (Age 48)
    Chief Financial Officer
  • Ms. Sheila Sponselee (Age 40)
    Chief People & Operations Officer
  • Ms. Sarah Cue Kiely
    Vice President of Investor Relations & Corporate Communications
  • Ms. Sandra van der Kolk
    Junior Financial Controller

PRQR Stock Analysis - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price target for 2024?

5 brokerages have issued 1 year price objectives for ProQR Therapeutics' shares. Their PRQR share price targets range from $1.80 to $5.00. On average, they expect the company's share price to reach $3.80 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2024?

ProQR Therapeutics' stock was trading at $1.98 at the beginning of 2024. Since then, PRQR shares have increased by 20.2% and is now trading at $2.38.
View the best growth stocks for 2024 here
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Wednesday, March, 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative trailing twelve-month return on equity of 56.71%.

What ETF holds ProQR Therapeutics' stock?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.04%), BNP Paribas Financial Markets (0.02%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRQR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners